Skip to main content
. Author manuscript; available in PMC: 2022 Nov 14.
Published in final edited form as: J Clin Immunol. 2020 Jan 28;40(2):418–420. doi: 10.1007/s10875-020-00751-4

Figure 1.

Figure 1

(A-E) Comparative photographs of the patient’s skin lesions, taken before dupilumab initiation (upper panels) and after one year of treatment (lower panels). From left to right, photographs of the patient’s head, forearms, left shoulder, left thigh and right flank. (F-G) Standardized SCORAD (Scoring Atopic Dermatitis) and DLQI (Dermatology Life Quality Index) scores at dupilumab initiation and at multiple time points on treatment. (H) Serum IgE levels before dupilumab initiation (mean of 7 separate samples) and at multiple time points on treatment. K-L) Levels of cytokines and chemokines in the patient’s serum, determined by LUMINEX methods, at dupilumab initiation and after six and 12 months on treatment. The black line represents the mean value for 10 healthy non-atopic individuals tested in parallel at a single time point. The dot lines represent the range of the values obtained for the 10 healthy individuals. The values are given in pg/ml. TARC: Thymus- and activation-regulated chemokine; MDC: Macrophage-derived chemokine.